COMPASS PATHWAYS PLC
(Exact Name of Registrant as Specified in Its Charter)

England and Wales
(State or other Jurisdiction of Incorporation)
001-39522
(Commission File Number)
Not applicable
(I.R.S. Employer Identification No.)

33 Broadwick Street
London W1F 0DQ
(Registrant’s Telephone Number, Including Area Code)
United Kingdom

+1 (646) 905-3974
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Depositary Shares, each representing one ordinary share, nominal value £0.008 per share</td>
<td>CMPS</td>
<td>The Nasdaq Global Select Market</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On July 19, 2022, COMPASS Pathways plc (the “Company”) announced that its board of directors has appointed Kabir Nath as the Company’s chief executive officer effective August 1, 2022. In this role, Mr. Nath will serve as the Company’s “principal executive officer” as such term is used for purposes of the rules and regulations of the U.S. Securities and Exchange Commission. Mr. Nath will also be appointed as a member of the board of directors as a Class II director effective as of August 1, 2022. Mr. Nath will stand for re-election to the board of directors in accordance with the Company’s articles of association at the Company’s 2023 annual meeting of shareholders. Mr. Nath is not expected to be named to any committee of the board of directors.

Mr. Nath, age 57, has approximately thirty years of experience in the biopharmaceutical and medical device industry. Mr. Nath is currently transitioning out of his role as senior managing director of global pharmaceuticals at Otsuka Holdings Co., Ltd., a leading global healthcare group listed on the Tokyo Stock Exchange (JP 4578), a position he has held since March 2020. From March 2016 until April 2022, Mr. Nath served as president and chief executive officer of Otsuka’s North America Pharmaceutical Business. Prior to Otsuka, from 2003 until December 2015, Mr. Nath held positions of increasing responsibility and leadership at Bristol-Myers Squibb Company (NYSE: BMS). Mr. Nath holds an M.A. from King’s College, University of Cambridge, and an M.B.A. from INSEAD.

There was no arrangement or understanding between Mr. Nath and any other person pursuant to which Mr. Nath was appointed as an officer or director. Mr. Nath is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended. There are no family relationships between Mr. Nath and any director or executive officer of the Company.

The Company entered into an employment agreement (the “Employment Agreement”), effective as of August 1, 2022, with Mr. Nath. The Employment Agreement has an initial term through the earlier to occur of (i) the date Mr. Nath relocates to the United Kingdom or (ii) December 31, 2023. On or before December 31, 2023, Mr. Nath will re-locate to the United Kingdom and will enter into a new agreement on substantially similar terms to this Employment Agreement and those of other UK-based executives at the Company.

Pursuant to the Employment Agreement, Mr. Nath is entitled to an annual base salary of $580,000 (upon Mr. Nath's relocation to the United Kingdom, such salary will be paid in pound sterling (“GBP”) and be equal to the greater of (i) £431,000 GBP or (ii) the GBP equivalent of $580,000 U.S. dollars calculated at the then-prevailing exchange rate) and is eligible to earn an annual incentive bonus, with a target bonus amount of 60% of his then-current annual base salary (and the ability to earn up to 125% of that target bonus amount in certain circumstances) as determined by the board of directors in its discretion. In addition, Mr. Nath will receive (i) a housing stipend of £12,000 per month through August 2023; (ii) a one-time reimbursement payment of up to $5,000 for attorneys’ fees; and (iii) a one-time cash payment of $250,000 when Mr. Nath relocates to the United Kingdom. Mr. Nath will receive no additional compensation for his services as a director of the Company. The Employment Agreement also provides that the Company will grant Mr. Nath (a) a non-qualified option to purchase up to 600,000 ordinary shares as an inducement grant at an exercise price per share equal to the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date and (b) 50,000 restricted share units under the Company’s 2020 Share Option and Incentive Plan. The equity awards will vest over four years as follows: one-fourth will vest on the first anniversary of the grant date and the remaining three-fourths will vest in 36 equal monthly installments.

Either party may terminate the Employment Agreement upon ninety (90) days’ written notice. The Company may terminate the Employment Agreement at any time for “cause” (as such term is defined in the Employment Agreement). Mr. Nath may terminate the Employment Agreement upon thirty (30) days’ written notice for “good reason” (as such term is defined in the Employment Agreement), subject to Company’s right to cure the deficiency. In the event the Company terminates Mr. Nath’s employment without “cause” or Mr. Nath terminates his
employment for “good reason”, Mr. Nath is entitled to a cash severance payment equal to one year’s annual salary plus the target annual bonus amount for the year in which such termination occurs.

The foregoing description of the Employment Agreement is a summary and does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Mr. Nath is also expected to enter into the Company’s standard Deed of Indemnity, the form of which was filed as Exhibit 10.6 to the Company’s registration statement on Form F-1/A filed with the Securities and Exchange Commission on September 14, 2020.

Transition of George Goldsmith to Executive Chairman

Effective August 1, 2022, George Goldsmith, the Company’s current chief executive officer and chairman of the board of directors, will be appointed as the Company’s executive chairman to facilitate the transition to a new chief executive officer. Mr. Goldsmith will serve as executive chairman until December 31, 2022 and thereafter will remain chairman of the board of directors. Mr. Goldsmith will continue to serve on the Company’s board of directors as a Class III director, with a term expiring at the Company’s 2023 annual meeting of shareholders and until his successor is duly elected and qualified, or, if sooner, until his earlier death, resignation or removal.

Executive Chairman Employment Agreement

In connection with his appointment as executive chairman, Mr. Goldsmith and the Company entered into an amendment to his employment agreement dated September 14, 2020 (the “Amended Employment Agreement”). Pursuant to the terms of the Amended Employment Agreement, Mr. Goldsmith will serve as executive chairman until December 31, 2022, at which time his employment will end, without the need for notice by either party.

Pursuant to the Amended Employment Agreement, Mr. Goldsmith is entitled to an annual base salary of £346,800 (approximately $414,200) and is eligible to receive an annual incentive bonus for the year ending December 31, 2022, with a target bonus amount of 55% of his base salary (and the ability to earn up to 125% of that target bonus amount in certain circumstances), notwithstanding the termination of his employment prior to the date of the bonus payment, provided, however, that such bonus amount shall be pro-rated to reflect his reduced salary for the period from August 1, 2022 to December 31, 2022. During this time, Mr. Goldsmith will receive no additional compensation for his services as a director of the Company.

The foregoing description of the Amended Employment Agreement is a summary and does not purport to be complete and is qualified in its entirety by reference to the Amended Employment Agreement, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

On July 19, 2022, the Company issued a press release titled "COMPASS Pathways Appoints Kabir Nath as Chief Executive Officer.” A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed herewith:

<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.1</td>
<td>Employment Agreement dated August 1, 2022 by and between COMPASS Pathways plc and Kabir Nath.</td>
</tr>
<tr>
<td>10.2</td>
<td>Amendment to Employment Agreement dated September 14, 2020 by and between COMPASS Pathways plc and George Goldsmith.</td>
</tr>
<tr>
<td>99.1</td>
<td>Press Release issued by COMPASS Pathways plc on July 19, 2022</td>
</tr>
<tr>
<td>104</td>
<td>Cover page interactive data file (embedded within Inline XBRL document)</td>
</tr>
</tbody>
</table>
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

COMPASS PATHWAYS PLC

Date: July 19, 2022

By: /s/ Matthew Owens

Matthew Owens
General Counsel and Chief Legal Officer
EMPLOYMENT AGREEMENT

This Employment Agreement (this “Agreement”) is effective as of 1 August 2022 (the “Effective Date”), and is entered into by and between the Company (hereinafter defined), and Executive (hereinafter defined) (collectively with the Company, the “Parties”; each of the Parties referred to individually as a “Party”).

WHEREAS, the Company desires to employ Executive in accordance with the terms and conditions set forth below; and

WHEREAS, Executive desires to be employed by the Company in accordance with the terms and conditions set forth below;

WHEREAS, the Parties acknowledge and agree that Executive will reside and work for the Company in the U.S through no later than 31 December 2023 upon which time Executive will relocate and work for Company in the U.K.;

WHEREAS, the Parties intend for this Agreement to govern Executive’s employment while residing in the U.S. and intend to execute a new agreement on substantially similar terms (but subject to U.K. law and practice) governing Executive’s employment while residing in the U.K.;

NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements set forth in this Agreement, the Parties hereby agree as follows:

PARTIES

(1) COMPASS PATHWAYS, INC., a Delaware corporation with a principal place of business at 180 Varick Street, 6th Floor New York, NY 10014, (the "Company"); and

(2) KABIR NATH of 115 North Union Street, Lambertville, NJ 08530 (the "Executive").

AGREED TERMS

1. Definitions

1.1 The following terms shall have the following meanings unless the context requires otherwise:

"Board" means the board of directors of the Company or any person or committee of the board duly appointed by it;

"Capacity" means agent, consultant, director, Executive, owner, partner, shareholder or otherwise;

"Confidential Information" means trade secrets, knowhow and information (whether or not recorded in documentary form, or stored on any magnetic or optical disk or memory) relating to the business, products, affairs and finances of any Group Company or any of their suppliers, customers, agents, shareholders or management, including (but not limited to): (a) business, financial or strategic information or plans; (b) technical data, research data and know-how; (c) litigation, potential litigation or legal advice; (d) employment terms; (e) commercial terms with business partners; (f) products or services in the course of development; (g) processes, techniques or know-how; (h) details of any joint ventures before or after the date of this agreement, whether or not such information is marked confidential;
"Copies" means copies or records of any Confidential Information in whatever form (including, without limitation, in written, oral, visual or electronic form or on any magnetic or optical disk or memory and wherever located) including, without limitation, extracts, analysis, studies, plans, compilations or any other way of representing or recording and recalling information which contains, reflects or is derived or generated from Confidential Information;

"Intellectual Property" means patents, rights to Inventions, copyright and related rights, trade marks, trade names and domain names, rights in get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world;

"Invention" means any invention, idea, discovery, development, notation, formula, improvement or innovation, whether or not patentable or capable of registration, and whether or not recorded in any medium;

"Termination" means the termination of the Executive’s employment under this Agreement however caused, whether with Cause or not, and "Termination Date" means the date of Termination.

1.2 In this Agreement, unless the context otherwise requires:

1.2.1 words in the singular include the plural and in the plural include the singular;

1.2.2 any phrase introduced by the terms "including", "include", "in particular" or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;

1.2.3 the headings are inserted for convenience only and shall not affect its construction;

1.2.4 reference to a particular law is a reference to it as it is in force for the time being taking account of any amendment, extension or re-enactment and includes any subordinate legislation for the time being in force made under it;

1.2.5 the Schedules, if any, shall form part of this Agreement, shall have effect as if set out in full in the body of this Agreement and any reference to this Agreement includes the Schedules; and

2. Term of Employment

Subject to earlier termination pursuant to Section 18, the term of this Agreement shall commence upon the Effective Date and shall continue until the earlier to occur of (i) the date Executive relocates to the United Kingdom or (ii) 31 December 2023 (the “Initial Term”). Effective upon expiration of the Initial Term, the Parties will enter into a new agreement substantially similar to this Agreement and those of other UK-based executives at the Company.
3. **Conditions and Warranties**

3.1 The Executive represents and warrants that:

3.1.1 the Executive is eligible to work in the United States and agrees to provide documentation to support such eligibility within the time period required by applicable law; and

3.1.2 the Executive is not bound by or subject to any written or oral agreement, pact, covenant, or understanding with any previous or concurrent employer, or any other party, that would limit, abridge, restrict, or interfere with, in any way, his ability to perform his duties and obligations hereunder.

3.1.3 That the performance of his duties and obligations hereunder shall not violate any written or oral agreement, pact, covenant, or understanding by and between him and any previous or concurrent employer, or any other party.

3.1.4 That he will not use any trade secret, or confidential or proprietary information, of any of his previous or concurrent employers, or that was obtained, learned, or procured during any period of employment prior to or concurrent with his employment with the Company, in connection with his employment with the Company or in the performance of his duties and obligations hereunder.

3.1 It is a condition of this employment that the Executive has and maintains during the course of this employment, valid United States citizenship or immigration status which permits the Executive to be employed by the Company in the role for which the Executive is employed, and authorization to travel to the United Kingdom when and if necessary, from time to time. The Executive must notify the Company immediately if at any time the Executive does not meet this condition.

3.2 If the Executive is in breach of any of the warranties or fails to satisfy the conditions set out in this clause 3, then the Company shall be entitled to terminate the Executive’s employment immediately and without payment of any severance or other benefits other than as required by law.

4. **Duties**

4.1 The Executive shall serve the Company as the Chief Executive Officer of the Company.

4.2 During the employment the Executive shall:

4.2.1 devote sufficient time, attention, effort, and skill to his position with and the business of the Company and any other Group Company for which the Executive is required to work from time to time;

4.2.2 faithfully and diligently exercise such powers and perform such duties for each Group Company as may from time to time be assigned by the Company;

4.2.3 comply with all reasonable and lawful directions given by the Board;
4.2.4 promptly make such reports to the Board in connection with the affairs of each Group Company on such matters and at such times as are reasonably required;

4.2.5 use their utmost endeavours to promote, protect, develop and extend the business of the Company;

4.2.6 comply with their common law, statutory, and regulatory laws, rules, regulations, licensing requirements, and fiduciary duties of, or that may be applicable to, his employment with the Company;

4.2.7 at all times conduct the business of each Group Company for which the Executive is responsible in a lawful and ethical manner; and

4.2.8 In the event that any term(s) of this Agreement conflicts with a term(s) of any handbook, policy, practice, or procedure adopted or maintained, at any time, by the Company, the term(s) of this Agreement shall control and supersede such conflicting term(s).

5. Regulatory Compliance and Policies and Procedures

5.1 The Executive will read and comply with:

5.1.1 any rules, policies and procedures that apply to each Group Company at all times; and

5.1.2 any other laws and regulations material to the conduct of the business of the Company or any Group Company.

5.2 Although the Company’s rules, policies and procedures may or may not form part of this Agreement, failure to comply with them may result in disciplinary action up to and including dismissal.

6. Place of Work

6.1 Executive’s principal place of employment shall be in the United States and the Parties anticipate that the majority of Executive’s business time shall be spent in such location, although substantial time may be spent, as part of Executive’s employment with the Company, in such other domestic and/or international locations as may be reasonably requested by the Company from time-to-time, for which Executive may be required to travel. Without limiting the general obligations of this clause, the Executive will be required to travel to the United Kingdom.

6.2 The Executive agrees to travel on any business of any Group Company (both within the United States, the United Kingdom and abroad) as may be required for the proper performance of the Executive’s duties.

7. Hours of Work

Executive acknowledges and understands that his position of employment with the Company is considered “exempt,” as that term is defined under the Fair Labor Standards Act and applicable state or local law(s). As an exempt Executive, Executive is not eligible to receive overtime pay.
8. **Salary**

8.1 The Company shall pay Executive a base salary equal to $580,000.00USD per year (as it may be adjusted from time to time, the “Annual Salary”), less applicable taxes, withholdings, any deductions required by law, and any deductions that may be authorized by Executive, from time to time, in accordance with applicable federal, state, and/or local law. The Annual Salary shall be payable in installments or otherwise in accordance with the Company’s standard payroll practices and procedures, as in effect from time to time.

8.2 The salary paid to the Executive may be reviewed annually. The Company is under no obligation to award an increase following a salary review.

8.3 The Executive will reimburse the Company upon demand for the personal use of any Company credit card, any other unauthorised transactions entered into by the Executive or any overpayments made to the Executive.

8.4 Upon relocation to the U.K., Executive’s annual base salary will be paid in GBP and be equal to the greater of (i) £431,000.00GBP or (ii) the GBP equivalent of $580,000.00USD calculated at the then-prevailing exchange rate as indicated in the Wall Street Journal.

9. **Expenses**

The Company shall reimburse any expenses necessarily incurred by the Executive in the proper performance of the Executive’s duties under this Agreement subject always to the rules and policies of the Company from time to time and subject to the Executive providing receipts or other evidence of payment as the Company may require.

10. **Annual Bonus**

10.1 The Executive shall be eligible to earn an annual discretionary bonus, in a gross target amount equal to 60% of the then-current Annual Salary (any bonus awarded hereunder shall hereinafter be referred to as an “Annual Bonus”). Whether to pay an Annual Bonus, and if so, the amount of any such bonus, shall be determined by the Board in its sole discretion. In setting the amount, if any, of any Annual Bonus, the Board shall in good faith consider the Company’s overall performance, as well as the Executive’s individual performance, including such terms or targets as the Board may communicate from time to time. The Board shall be entitled to determine, in its sole discretion, whether such targets have been met and where such targets have been met in full or part shall have the discretion to determine whether to make payments and, if so, in what amount. Any Annual Bonus will be paid within 90 days following the end of the fiscal year in which the applicable services were performed, in accordance with the Company’s bonus payment practices in effect from time to time for similarly-situated Executives of the Company, subject to all applicable withholdings and/or deductions. In order to earn, accrue, and receive any Annual Bonus, Executive must be actively employed by the Company and in good standing, as determined by the Board in its discretion, without having received from or tendered to the Company notice of termination or anticipated termination (for any reason) at the time that such bonus is to be paid to Executive. Bonus entitlement does not accrue in the course of a year, and the Executive is not entitled to payment of a bonus, or any pro rata portion of it, if the Executive leaves employment prior to the date that the bonus is paid. Payment of a bonus for any year will not give rise to an entitlement or expectation of a bonus for any other year. Any entitlement to a bonus shall also be subject to any additional requirements of any Company bonus plan that may be in place from time to time.
10.2 The Board may suspend, alter or discontinue any bonus payment(s) or any bonus plan and its eligibility requirements at any time (whether generally or in relation to the Executive only) at its absolute discretion. If the Executive receives any bonus payment the Company is not obliged to make any further bonus payments and any bonus payment will not become part of the Executive's contractual remuneration or fixed salary.

10.3 Upon relocation to the U.K., Executive's Annual Bonus will remain a gross target amount equal to 60% of the then-current GBP annual base salary.

11. Benefit Plans

11.1 The Executive shall, during employment, be entitled to participate in any and all medical insurance, group health, disability insurance, life insurance, incentive, savings, retirement, and other benefit plans, if any, which are made generally available to similarly-situated Executives of the Company (and subject to eligibility requirements, enrollment criteria, and other terms and conditions of such plans), and which the Company, in its sole discretion, may at any time amend, modify, or terminate, subject to the terms and conditions of such plans and applicable federal, state, or local law.

11.2 The Company’s obligation under this clause is limited to paying premiums to the relevant benefits provider. If the benefit provider refuses to accept a claim under the relevant benefit plan the Company shall have no obligation or responsibility to challenge that decision or to compensate the Executive.

11.3 Upon relocation to the U.K., Executive will be entitled to participate in the Company’s benefit plans (including pension plan) generally available to similarly-situated U.K. executives of the Company, as amended from time to time. U.S. benefit and pension plans will no longer be provided to Executive.

12. Vacation

The Executive shall be entitled to vacation in accordance with and subject to applicable law and Company policy as may be in effect from time to time. The Company reserves the right, in its discretion, to change such policy subject to applicable law. Executive's current vacation time is equal to 25 days.

Upon relocation to the U.K., Executive’s vacation and sick leave will be subject to the Company’s U.K. policy and U.K. law, as in effect from time to time.

13. Sick Leave

13.1 The Executive shall be entitled to paid sick leave in accordance with and subject to applicable law and Company policy as may be in effect from time to time. The Company reserves the right, in its discretion, to change such policy subject to applicable law.

13.2 The rights of the Company to terminate the Executive’s employment under the terms of this Agreement apply even when such termination would or might cause the Executive to forfeit any entitlement to sick pay, permanent health insurance or other benefits, unless applicable law requires otherwise.
14. **Outside Activities and Interests**

14.1 The Executive shall not during the employment, except as a representative of the Company or with the Board’s prior written consent, whether directly or indirectly, paid or unpaid, be employed, engaged, concerned or interested in any other actual or prospective business, organization, occupation or profession.

14.2 Nothing in this Agreement shall prevent the Executive from holding an investment by way of shares or other securities to in any entity listed or dealt on a recognized stock exchange (a “Permitted Investment”) provided always that during the term of the employment: (i) the Permitted Investment shall not constitute more than 3% of the issued share capital of the entity concerned, and (ii) the Executive makes full disclosure of such Permitted Investments and any actual or apparent conflicts of interest resulting therefrom, so that the Company can make appropriate determinations on the propriety of any investment.

15. **Confidential Information**

15.1 Executive acknowledges that during his employment with the Company, and by the nature of Executive’s duties and obligations hereunder, Executive will come into close contact with Confidential Information of the Company and its subsidiaries, affiliates, and/or other related entities, as applicable. Confidential Information does not include: (i) Executive’s general skills and experience; (ii) information that was lawfully in Executive’s possession prior to his employment with the Company (other than through breach by a third party of any confidentiality obligation to the Company); (iii) information that is or becomes publicly available without any direct or indirect act or omission on Executive’s part; (iv) information that is required to be disclosed pursuant to any applicable law, regulation, judicial or administrative order or decree, or request by other regulatory organization having authority pursuant to the law; provided, however, that, except as set forth in and subject to Section 15.4 of this Agreement, Executive shall first have given reasonable notice to the Company prior to making such disclosure; or (v) information that is generally known within the industries or trades in which the Company transacts business.

15.2 Executive acknowledges and agrees that each and every part of the Company’s Confidential Information: (a) has been developed by the Company at significant effort and expense; (b) is sufficiently secret to derive economic value from not being generally known to other parties; (c) is proprietary to and a trade secret of the Company and, as such, is a valuable, special, and unique asset of the Company; and (d) constitutes a protectable business interest of the Company. Executive further acknowledges and agrees that any unauthorized use or disclosure of any Confidential Information by Executive will cause irreparable harm and loss to the Company. Executive acknowledges and agrees that the Company owns the Confidential Information. Executive agrees not to dispute, contest, or deny any such ownership rights either during or after Executive’s employment with the Company.

15.3 In recognition of the foregoing, and except as set forth in and subject to Section 15.4 of this Agreement, Executive covenants and agrees as follows:

   i. Executive will use Confidential Information only in the performance of his duties and obligations hereunder for the Company;

   ii. Executive will take all necessary and reasonable steps to protect Confidential Information from being disclosed to
anyone within the Company who does not have a need to know the information and to anyone outside of the Company; and

iii. Promptly upon Executive’s termination, and in any event no later than three (3) business days after Executive’s employment with the Company ceases, Executive shall return to the Company any and all Confidential Information in his possession, custody, or control.

15.4 Executive acknowledges and agrees that his obligations under this Section 15 of the Agreement shall remain in effect indefinitely.

Notwithstanding the foregoing, nothing in this Agreement shall be construed as, or shall interfere with, abridge, limit, restrain, or restrict Executive’s (or his attorney’s) right, without prior authorization from or notification to the Company: (i) to communicate with any federal, state, or local government agency charged with the enforcement and/or investigation of claims of discrimination, harassment, retaliation, improper wage payments, or any other unlawful employment practices under federal, state, or local law, or to file a charge, claim, or complaint with, or participate in or cooperate with any investigation or proceeding conducted by, any such agency; (ii) to report possible violations of federal, state, or local law or regulation to any government agency or entity, including but not limited, to the extent applicable, to the U.S. Department of Labor, the Department of Justice, the Securities and Exchange Commission (the “SEC”), the Congress, and/or any agency Inspector General, or make other disclosures that are protected under the whistleblower provisions of federal, state, or local law or regulation; or (iii) to communicate directly with, respond to any inquiry from, or provide testimony before, to the extent applicable, the SEC, the Financial Industry Regulatory Authority, any other self-regulatory organization, or any other federal, state, or local regulatory authority, regarding this Agreement or its underlying facts or circumstances.

In addition, Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, in the event that Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to his attorney and use the trade secret information in the court proceeding, if Executive: (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.

16. Reporting Obligation

16.1 It is the duty of the Executive to report to the Board any material breach by any Executive, Executive or Group Company of their legal obligations of which the Executive is aware. Concerns should be reported, in writing, to the Board.

16.2 Whilst it is the Company’s clear policy to operate in an ethical and lawful manner and to foster an environment which facilitates the internal reporting of matters of concern for the avoidance doubt nothing in this Agreement prevents the Executive from reporting any regulatory
breaches to any regulator or reporting any criminal conduct to the relevant authorities.

17. **Intellectual Property**

17.1 All Intellectual Property is exclusively the property of the Company. Executive will promptly disclose in writing, in full detail to persons authorized by the Company, all Intellectual Property which Executive conceives, creates, makes, or develops during his employment with the Company, which relate either to Executive’s work assignment with the Company, or the trade secrets, confidential or proprietary information, business, or potential business of the Company, for the purpose of determining the Company’s rights in such Intellectual Property. Executive agrees he will not file any patent application, or other application seeking intellectual property rights relating to any such Intellectual Property without the prior written consent of the Company’s General Counsel or his/her designee. If Executive does not prove that Executive conceived or made the Intellectual Property entirely after leaving the Company’s employment, the Intellectual Property is presumed to have been conceived or made during the period of time Executive was employed by the Company, and Executive agrees to assign said Intellectual Property to the Company.

17.2 The term “Intellectual Property” excludes any software program, application program interface, equipment, supplies, resources, facilities, data, products, information, materials, or trade secrets used by the Company, and which was developed entirely on Executive’s own time, unless said Intellectual Property: (i) relates to the Company’s business or potential business; or (ii) results from tasks assigned to Executive by the Company or from work performed by Executive for the Company.

17.3 All Intellectual Property will belong solely to the Company from conception. The Company shall be the sole owner of all issued patents, pending patent applications, before any relevant authority worldwide (including any additions, continuations, continuation-in-part, divisional, reissue, reexaminations, renewals or extensions based thereon), copyrights and other works of authorship, domain names, trade secrets, trademarks, service marks, and all other intellectual property or other rights (collectively, the “Proprietary Rights”) in connection with all Intellectual Property in the United States and/or in any other country. Executive further acknowledges and agrees that such Intellectual Property and other works of authorship shall be deemed “works made for hire” as defined in the U.S. Copyright Law, 17 U.S.C. § 101 et seq. (as amended), and were prepared by Executive within the scope of his employment with the Company, for purposes of the Company’s rights under copyright laws, and are owned by the Company. To the extent that title to any Intellectual Property or any materials comprising or including any Intellectual Property, e.g., derivative work, including all Proprietary Rights embodied therein, does not, by operation of law, vest in the Company, or is not considered “works made for hire,” Executive hereby irrevocably assigns to the Company all of his rights, title and interest to that Intellectual Property, including all Proprietary Rights embodied therein, free of all encumbrances and restrictions. At any time during or after Executive’s employment with the Company that the Company requests, Executive will cooperate, and take any action, including signing whatever written documents of assignment the Company deems reasonably necessary, to formally evidence Executive’s irrevocable assignment to the Company of any Intellectual Property and all related
Exhibit 10.1

Proprietary Rights, and, upon the Company’s request, he shall deliver to the Company any documents which the Company deems necessary to effect the transfer or prosecution of rights for all Intellectual Property and Proprietary Rights in the United States and/or in any other country. At all times during and after Executive’s employment with the Company, Executive will cooperate and assist the Company in obtaining, maintaining and renewing patent, copyright, trademark and other appropriate protection for any Intellectual Property, in the United States and in any other country, at the Company’s expense. In the event that the Company is unable, after reasonable effort, to secure Executive’s signature on any document or documents needed to apply for or prosecute any patent, copyright, domain name, trademark, or other right or protection relating to Intellectual Property, for any other reason whatsoever, Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on Executive’s behalf to execute and file any such application or applications, and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyrights, domain names, trademarks, or similar protections thereto with the same legal force and effect as if executed by Executive. With respect to Intellectual Property owned by the Company, Executive hereby waives all rights of publicity, moral rights or droit morale, and agrees not to enforce or permit others to enforce such rights against the Company or its successors in interest.

17.4 Executive hereby grants to the Company a license to use, without further compensation or approval from Executive, Executive’s name, image, portrait, voice, likeness, and all other rights of publicity, or any derivative or modification thereof that the Company may create, in any and all mediums, now known or hereafter developed, provided that such use is in relation to the Company’s business and consistent with professional business standards, and does not disparage Executive; provided, however, that if written notice is provided to the Company by Executive following termination of Executive’s employment (for any reason) requesting that the Company cease using Executive’s likeness, the Company shall have 30 calendar days to cease using Executive’s likeness in the manner set forth in the notice.

18. Termination

18.1 The Company and Executive agree that this Agreement, and Executive’s employment with the Company, shall terminate upon the earliest to occur of the following events:

i. mutual written agreement of the Company and Executive;

ii. termination of Executive’s employment by the Company with Cause. For purposes of this Agreement, the term “Cause” shall mean: (a) any act or omission of Executive that, in connection with his employment with the Company, amounts to or constitutes a breach of a fiduciary duty, gross negligence, willful misconduct, or material misconduct, or that amounts to or constitutes fraud, embezzlement, or misappropriation; (b) Executive’s breach of any term(s) of this Agreement; (c) Executive’s violation of any policy(ies) established, adopted, or maintained by the Company; (d) any act or omission of Executive that is demonstrably and materially injurious to the Company; (e) any act or omission of Executive that causes the
Company to suffer or endure public disgrace, disrepute, or economic harm; (f) Executive’s misappropriation of corporate assets or corporate opportunities; (g) Executive’s conviction of a felony, a crime involving financial dishonesty towards the Company, or a crime involving moral turpitude; or (h) Executive’s failure to follow the reasonable directives of the Company or to perform the material responsibilities or duties of his position; provided, however, that, in the event that the applicable act, event, or occurrence constituting “Cause” may be or is capable of being cured by Executive, “Cause” shall not be deemed to exist with respect to such act, event, or occurrence unless (x) the Company has delivered to Executive a written notice (email to suffice) providing Executive with 30 calendar days to cure such act, event, or occurrence and (y) Executive has failed to cure such act, event, or occurrence within the 30-day cure period;

iii. termination of Executive’s employment by the Company, upon 90 calendar days’ prior written notice to Executive, without Cause (or payment in lieu thereof);

iv. termination of Executive’s employment by Executive with Good Reason, provided that Executive has first provided written notice of such reason to the Company no later than thirty (30) days after the event or occurrence constituting Good Reason first arises, with such notice affording the Company thirty (30) days, from the date of the Company’s receipt of such notice, to cure the deficiency, and further provided that, upon such cure by the Company, “Good Reason” shall not be deemed to exist for purposes of this Agreement. The term “Good Reason” shall mean the occurrence of any of the following events without the consent of Executive: (a) a material breach of this Agreement by the Company; (b) a material reduction in the Annual Salary or target Annual Bonus; or (c) a material reduction in Executive’s responsibility, authority, or duties relative to Executive’s responsibility, authority or duties in effect immediately prior to such reduction, except for any change in title or reporting relationship (such title or reporting change shall not constitute Good Reason);

v. termination of Executive’s employment by Executive, upon 90 calendar days’ prior written notice to the Company, without Good Reason (or payment in lieu thereof); or

vi. death or Disability of Executive. Executive shall be deemed to be “Disabled” if he is unable to perform the essential functions of his position, with or without a reasonable accommodation, for either 120 consecutive days, or 180 aggregate days in a twelve-month period, by reason of any physical or mental impairment.

18.2 The rights of the Company under clause 18.1 are without prejudice to any other rights that it might have at law to terminate the Executive’s employment or to accept any breach of this Agreement by the Executive as having brought the Agreement to an end. Any delay by the Company in exercising it rights to terminate shall not constitute a waiver thereof.

18.3 In the event of termination pursuant to section 18.1 (iii) or (iv) hereunder, Executive shall be entitled to severance in the amount equal to the sum of one year’s annual base salary and the target Annual Bonus for
the year in which termination occurs. Severance under this section shall be paid to Executive in a lump sum within thirty (30) days of the termination of his employment.

19. **Housing, Relocation Allowance, Initial Equity Grant and Attorneys’ Fees**

19.1 The Company shall pay the Executive a cash contribution towards housing costs of £12,000GBP per month from the Effective Date until August 2023 subject to deductions required by law and payable in accordance with the provisions for payment of the Executive’s basic salary contained in clause 8.1. For the avoidance of doubt, the housing contribution will not form part of the Executive’s basic salary for any purpose and will not be pensionable nor considered in the calculation of any bonus referred to in clause 10.

19.2 The Company shall pay the Executive a one-time cash contribution towards moving and relocation costs of $250,000USD at the time the Executive relocates to the United Kingdom, which shall be no later than 31 December 2023. Such contribution shall be subject to deductions required by law. For the avoidance of doubt, the contribution will not form part of the Executive’s basic salary for any purpose and will not be pensionable nor considered in the calculation of any bonus referred to in clause 10.

19.3 The Company shall make an initial grant of equity in the amount of 600,000 options and 50,000 RSUs in accordance with Company’s policies and procedures with respect to the granting of equity.

19.4 The Company will reimburse Executive for the actual cost incurred by Executive of attorneys’ fees in the review and negotiation of this Agreement. Said reimbursement will not in any event exceed $5,000.00USD.

20. **Obligations Upon Termination**

20.1 On Termination or, if requested earlier, the Executive shall:

20.1.1 immediately deliver to the Company all documents, books, materials, records, correspondence, papers, copies, Confidential Information and other business information (on whatever media and wherever located) relating to the business or affairs of any Group Company or its business contacts, any keys and any other property of any Group Company, which is in the Executive’s possession or control; and

20.1.2 delete any information relating to the business of any Group Company stored on any magnetic or optical disk or memory (including on any personal computer, personal device, personal email account or web account), and all matter derived from such sources which is in their possession or under their control outside the premises of the Company.

21. **Shares**

21.1 The Executive may at the absolute discretion of the Company be granted an option or other award over shares in the Company. Any
such option or award shall be governed by rules set by the Company and which may be varied from
time to time by the Company. Any such options or awards are not benefits conferred by this contract
of employment.

21.2 If on termination of this Agreement, whether lawfully or in breach of contract, the
Executive loses any rights or benefits in relation to any awards or options the Executive held
immediately prior to such termination of this Agreement ("Other Awards") which the Executive
would not have lost had the Agreement not been terminated (for example, the Executive is not
employed as at a vesting date and therefore options which would have vested on that date lapse) the
Executive shall not be entitled to be compensated for any such loss.

22. Post Termination Restrictions

In consideration for the Company’s offer to employ Executive under the terms herein, the Executive agrees
that Schedule 1 shall take effect.

23. General

23.1 A notice given to a party under this Agreement shall be in writing in the English language
and signed by or on behalf of the party giving it. It shall be delivered by hand or sent to the party at
the address given for that party in this Agreement, in the case of the Executive to their personal email
address or as otherwise notified in writing to the other party. A notice given by email shall be deemed
to take effect one hour after it is sent, a notice sent by first class post shall be deemed to take effect on
the next working day and notice sent by courier upon delivery at the address in question. A notice
required to be given to the Company under this Agreement shall not be validly given if sent by email.

23.2 This Agreement, together with all exhibits and schedules annexed hereto, constitutes the
entire agreement between the Parties relating to the subject matter hereof, and supersedes all prior
agreements and understandings, whether oral or written, with respect to the same. In entering into and
performing under this Agreement, neither the Company nor Executive has relied upon any promises,
representations, or statements except as expressly set forth herein. No modification, alteration,
amendment, revision of, or supplement to this Agreement shall be valid or effective unless the same
is memorialized in a writing signed by both by Executive and a duly-authorized representative or
agent of the Company.

23.3 The Executive agrees that in entering into this Agreement the Executive does not rely on
and shall have no remedies in respect of, any statement, representation, assurance or warranty
(whether made innocently or negligently) that is not expressly set out in this Agreement. The

23.4 No variation or agreed termination of this Agreement shall be effective unless it is in
writing and signed by the parties (or their authorised representatives).

23.5 The Executive shall not be contractually entitled to receive any benefit from the Company
which is not expressly provided for by this Agreement.
23.6 This Agreement may be executed in any number of counterparts, each of which, when executed and delivered, shall be an original, and all the counterparts together shall constitute one and the same agreement.

23.7 This Agreement shall in all respects be interpreted, enforced, and governed by and in accordance with the internal substantive laws (and not the laws of choice of laws) of the State of New Jersey.

Executive: /s/ Kabir Nath
Kabir Nath
Date June 28, 2022

Company (Compass Pathways, Inc.)

/s/ George Goldsmith
George Goldsmith
Date June 27, 2022
SCHEDULE 1
POST TERMINATION RESTRICTIONS

(1) In this Schedule, the following terms not otherwise defined in the Agreement shall have the following meanings unless the context requires otherwise:

"Look Back Period" the period of 12 months before the Termination Date;

"Restricted Business" those parts of the business of the Company and any Group Company with which the Executive was either:

(a) involved to a material extent; or
(b) privy to Confidential Information, in each case during the Look Back Period.

"Restricted Client" any firm, company or person who, during the Look Back Period was either a client or customer of or was otherwise in the habit of dealing with the Company or any Group Company and with whom or which the Executive either:

(a) had material personal contact; or
(b) was privy to Confidential Information, in each case during the Look Back Period.

"Restricted Prospective Client" any firm, company or person who was a prospective client or customer of the Company or any Group Company with whom or which the Company or any Group Company has been in negotiations during the Look Back Period or had expended significant time or resources and with whom or which the Executive:

(a) had material personal contact; or
(b) was privy to Confidential Information, in each case during the Look Back Period.

“Restricted Subject Matter Expert” means anyone employed or engaged by the Company or any Group Company who holds a high degree of technical experience in their area (such that their replacement would be costly and/or disruptive to the Company or any Group Company’s business) and with whom the Executive had material dealings during the period of 12 months immediately preceding the Termination Date in the course of the Executive’s employment.

“Supplier” means any person, firm, company or entity who during the period of 12 months immediately preceding the Termination Date was a supplier of services to the Company or any Group Company and with whom the Executive had material contact during the period of 12 months immediately preceding the Termination Date in the course of their employment.

“Competitor” means any person, firm, company of entity that the Executive joins, works for as an employee or contractor, or otherwise assists, that has a business, product or service that is competitive with the a business product or service provided by the Company following the termination of his employment with the Company.

(2) In order to protect the Confidential Information, trade secrets and business connections of the Company and each Group Company to which the Executive has access as a result of the employment, the Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that the Executive shall not:
(c) for twelve (12) months after the Termination Date, solicit or endeavour to entice away from the Company or any other Group Company the business or custom of a Restricted Client in competition with any Restricted Business, unless the Competitor has already solicited or conducted business with the Restricted Client; or

(d) for twelve (12) months after the Termination Date, be involved with the provision of products or services to (or otherwise have any business dealings with) any Restricted Client in the course of any business concern which is in competition with any Restricted Business, unless the Competitor has already conducted Restricted Business with the Restricted Client; or

(e) for twelve (12) months after the Termination Date, solicit or endeavour to entice away from the Company or any other Group Company the business or custom of a Restricted Prospective Client in competition with any Restricted Business, unless the Competitor already does business with the Restricted Prospective Client or has already solicited theRestricted Prospective Client; or

(f) for twelve (12) months after the Termination Date, be involved with the provision of products or services to (or otherwise have any business dealings with) any Restricted Prospective Client in the course of any business concern which is in competition with any Restricted Business, unless the Competitor already does business with the Restricted Prospective Client or has already solicited the Restricted Prospective Client for Restricted Business; or

(g) for twelve (12) months after the Termination Date, in the course of any business concern which is in competition with any Restricted Subject Matter Expert, employ or engage or otherwise facilitate the employment or engagement of any Restricted Person, whether or not such person would be in breach of contract as a result of such employment or engagement, unless the Restricted Person applies for employment or otherwise seeks affiliation with a Competitor without solicitation by Executive; or

(h) for twelve (12) months after the Termination Date, solicit, entice away or interfere with the Company’s or any Group Company’s relationship with or endeavour to solicit, entice away or interfere with the Company’s or any Group Company’s relationship with any Supplier, unless Competitor already does business with the Supplier;

(i) for twelve (12) months after the Termination Date, be employed by, work for the benefit of, engaged by, interested in or concerned with any for-profit or not-for-profit entities with a focus on improving mental health care through integrated therapeutic, diagnostic, psychological support and/or digital models of care.

(3) The Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that the Executive shall not at any time after the Termination Date, represent any connection with any Group Company in any Capacity, other than as a former Executive, or use any registered business names or trading names associated with any Group Company.

(4) None of the restrictions in this Schedule shall prevent the Executive from holding a Permitted Investment.

(5) The restrictions imposed on the Executive by this Schedule apply to the Executive acting:

(a) directly or indirectly; and
(b) in any Capacity, on their own behalf or on behalf of, or in conjunction with, any firm, company or person.

(6) If the Executive receives an offer to be involved in a business concern in any Capacity during employment, or before the expiration of the restrictions set out in paragraph (2) above, the Executive shall give the person making the offer a copy of this Schedule and shall tell the Company the identity of that person as soon as possible after accepting the offer.

(7) Each sub-paragraph (2)(a) to (2)(g), each definition set out in this Schedule, each limb of each such definition and each operative word within each sub-paragraph or definition is agreed to be a separate and severable restriction, notwithstanding that they are combined together for the sake of brevity. The parties agree that if any such restrictions shall be held to be void but would be valid if part of: (a) the wording of such restriction were deleted, such restriction shall apply with such deletion (including but not limited to a single word or words) as may be necessary to make it valid or effective; and (b) the wording of any definition were deleted, such restriction shall apply with such deletion as may be necessary to make it valid or effective but the deletion in that definition shall not apply to any other restriction, so that each definition is deemed to be repeated each time it is used. The parties agree that if any such restrictions shall be held to be void on account of its duration, the duration of each restriction shall take effect as if reduced by a month, until the resulting period shall be valid and enforceable.

(8) If the Executive breaches any of the provisions in this Schedule the Company may elect to extend the period during which the relevant breached provisions apply by a length of time equal to the period during which the breach continues, such additional period to commence on the date on which the original period would have expired. The Executive agrees that the Company's right to apply for injunctive relief or damages is not prejudiced by this clause.

(9) The Executive enters into each of the restrictions in this Schedule for the benefit of the Company on its own behalf and as trustee for each Group Company. The Executive will, at the request and expense of the Company, enter into a separate agreement with any Group Company in which the Executive agrees to be bound by restrictions corresponding to those restrictions in this Schedule in relation to that Group Company.

(10) The Executive acknowledges that if the Executive breaches the restrictions set out in this Schedule the Company will suffer irreparable loss, damages will not be an adequate remedy and the Company should be entitled to injunctive relief.
Dear George,

Changes to your service agreement

This letter confirms the following changes to your service agreement with COMPASS Pathfinder Limited dated 14 September 2020 (Service Agreement), will take effect from 1 August 2022:

1. Clause 2.1 of the Service Agreement shall be deleted in its entirety and replaced with the following:

   “The Executive’s employment under the terms of this Agreement shall continue, subject to the remaining terms of this Agreement, until it terminates on 31 December 2022 without the need for notice.”

2. Clause 4.1 of the Service Agreement shall be deleted in its entirety and replaced with the following:

   “The Executive shall serve as the Executive Chairman of the Company.”

3. Clause 8.1 of the Service Agreement shall be deleted in its entirety and replaced with the following:

   “The Executive shall be paid a basic salary of £346,800 per annum subject to deductions required by law. The Executive’s salary shall accrue from day to day, shall be payable in equal monthly instalments in arrears on or about the last Friday of each month and shall include any directors’ fees.”

4. A new Clause 10.4 shall be added to the Service Agreement:
“Any bonus due to the Executive pursuant to clause 10 shall be pro rated to reflect the Executive’s reduced salary for the period 1 August 2022 to 31 December 2022. Notwithstanding clause 10.2, the Executive shall not lose any entitlement to a bonus solely on the basis that he is not employed by the Company as at the payment date as a result of the expected termination of this Agreement on 31 December 2022.”

The remaining terms of your Service Agreement shall remain unchanged.

This letter may be executed in any number of counterparts, each of which is an original and which together have the same effect as if each party had signed the same document.

This letter has been duly executed and delivered as a deed on the date first stated above.

EXECUTED and DELIVERED as a DEED by
for and on behalf of
COMPASS Pathfinder Limited

/s/ Matthew Owens
Director

in the presence of:
Signature of witness /s/ Meredith Prithviraj
Name of witness Meredith Prithviraj
Address of witness
c/o COMPASS Pathways
180 Varick Street
New York, NY 10014
Occupation of witness Attorney
EXECUTED and DELIVERED as a DEED
by George Goldsmith

in the presence of:
Signature of witness /s/ Ekaterina Malievskaya
Name of witness Ekaterina Malievskaya
Address of witness
2, 10 Connaught Place
London W2 2ET
UK
Occupation of witness Chief Innovation Officer
COMPASS Pathways Appoints Kabir Nath as Chief Executive Officer

*Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care*

George Goldsmith remains COMPASS’ Chairman

London, UK – July 19, 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Kabir Nath as Chief Executive Officer, effective August 1, 2022. George Goldsmith, COMPASS’ current CEO and Chairman, will serve as the company’s Executive Chairman from August 1, 2022 to December 31, 2022 to facilitate the transition, and remain as Chairman after that.

Kabir Nath brings decades of experience in the health care industry to his new role, most recently serving as Senior Managing Director of global pharmaceuticals at Otsuka Pharmaceutical Co., Ltd. and previously as President and CEO of Otsuka’s North America Pharmaceutical Business, where he led the development of pharmaceutical products and digital solutions addressing complex mental health needs. Prior to Otsuka, Kabir held various leadership positions at Bristol Myers Squibb, a global biopharmaceutical company focused on innovative medicines for patients with serious diseases. Kabir holds an MA in Mathematics from the University of Cambridge and an MBA from INSEAD.

George Goldsmith, current CEO and Chairman of COMPASS Pathways, said, “We founded COMPASS Pathways to transform mental health care by creating a personalised, predictive and preventative model of care. As we enter the next stage of development, Kabir brings a track record of successful strategic growth and a deep dedication to this mission. Working alongside our talented leadership team, he will leverage his extensive background in leading the commercialisation of innovative therapies to bring COMP360 psilocybin therapy to the large number of patients who are not currently being helped by existing treatments.”

“I have a deep appreciation for the mission, scientific rigour and commitment to innovation of the COMPASS team who are developing evidence-based and accessible options for some of the world’s most serious mental health conditions,” said Kabir Nath. “I had the good fortune of being able to establish a strong working relationship with George, his co-founder Ekaterina Malievskaia and some of the COMPASS leadership team and Board members through Otsuka’s investment in COMPASS’ Series B investment round. I have seen first-hand how their passion for this company continues shaping the future of mental health care. I am grateful for this opportunity and excited to execute COMPASS’ vision, bringing its work to the next level to achieve better health outcomes for patients.”

In his new role, Kabir will continue building on COMPASS’ success and advancing patient access to evidence-based technology-enabled innovative care models combining pharmacological, psychological and digital solutions.

George Goldsmith will continue in his role as Chairman helping shape COMPASS’ leadership in public-private partnerships, advocacy and policy efforts to improve outcomes in mental health at scale.

Having established COMPASS Pathways in 2016, George has overseen COMPASS’ growth from start-up to a leader in the mental health care field through COMPASS’ ground-breaking initial public offering in 2020. His expertise and support of COMPASS’ regulatory efforts enabled the company to achieve FDA breakthrough therapy designation and Innovative Licensing and Access Pathway (ILAP) designation in
the UK for patients suffering with treatment-resistant depression (TRD). He also developed partnerships with leading academic institutions and the UK National Health Service, oversaw the build out of the company’s advanced Machine Learning, AI and digital health research capabilities, and helped lead the largest randomised controlled double-blind studies of COMP360 therapy in healthy volunteers and patients with treatment-resistant depression, pioneering integrative therapies that can create value for health systems and bring renewed hope for millions of patients worldwide.

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. [www.compasspathways.com](http://www.compasspathways.com)

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, the safety or efficacy of COMP360 psilocybin therapy as a treatment for depression, COMPASS’s business strategy and goals, including its ability to obtain regulatory approval of its product candidates, including COMP360, and to launch and commercialise products, COMPASS’s ability to continue to advance its research or develop plans to bring its product candidates to patients, including COMP360, and COMPASS’s expectations regarding the benefits of its psilocybin therapy. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s most recent annual report on Form 10-K or
quarterly report on Form 10-Q and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC's website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

Enquiries

Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324